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1 |  INTRODUCTION
Leukostasis, that is, symptomatic hyperleukocytosis (HL), is a 
medical emergency condition characterized by HL and symp-
toms of diminished tissue perfusion. Leukostasis requires 
rapid treatment in order to prevent life‐threatening complica-
tions and early death. HL is a laboratory abnormality and is 
most often defined as a total leukemia blood cell count >50 
or >100 × 109/L.1 HL develops due to leukemic cell prolif-
eration and may occur in acute leukemias or chronic myeloid 
leukemia in the accelerated phase.2,3 Complications of HL in-
clude leukostasis, disseminated intravascular coagulation, and 
tumor lysis syndrome. Leukostasis is most often seen in acute 
myeloid leukemia (AML) because of the large and poorly de-
formable blasts in AML.1 Leukostasis evolves as a result of in-
creased blood viscosity and sludging of the leukocytes leading 
to mechanical obstruction of the microcirculation and hence 
altered tissue perfusion, primarily in the lungs, brain, and kid-
neys.3 High oxygen consumption and invasiveness of leukemic 
blast cells may contribute to the organ dysfunction in leukosta-
sis.2 Also, a role for adhesion receptors and cytokines has been 
suggested as a pathogenic factor.4 One‐week mortality of leu-
kostasis is 20%‐40% if left untreated and rises to 90% with the 
presence of respiratory failure and neurological compromise.1
We present a case in which transformation to AML leads 
to acute fatal right‐sided heart failure in a patient with myel-
odysplastic syndrome (MDS).
2 |  CASE REPORT
A 70‐year‐old woman with MDS refractory anemia and ex-
cess blasts (RAEB)‐2 type with cytogenetic deletion xq was 
admitted to the emergency department due to uncharacteris-
tic symptoms in terms of fever, dyspnea, vomiting, and di-
arrhea. The patient had finished treatment with azacitidine 
5 days prior to admission and had started in hydroxycarba-
mide treatment due to asymptomatic HL. Total white blood 
cell (WBC) count was 51.4 × 109/L and 132 × 109/L 14 and 
7 days prior to admission, respectively. The patient had a 
normal echocardiogram and electrocardiogram (ECG) at 
20 months and two months prior to admission, respectively 
(Figures 1A and 2A,B). Except for essential hypertension, 
the patient had no other known cardiovascular risk factors. 
At admission to hospital, the patient was neurological intact 
but with tachypnea, tachycardia of 115 bpm and a blood pres-
sure of 95/60. Fluid and empiric antibiotic treatment were 
initiated with a tentative diagnosis of neutropenic fever. 
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Key Clinical Message
We document leukostasis leading to acute fatal right‐sided heart failure. In patients 
presenting with leukostasis and cardiopulmonary symptoms, clinicians should aim to 
assess for cardiac involvement, that is, by ECG and acute echocardiogram, since 
early recognition of right ventricular disease may provide an opportunity to treat this 
potentially reversible condition.
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However, despite volume and antibiotic therapy, the patient 
experienced respiratory worsening, epigastric pain and dem-
onstrated rapid hemodynamic deterioration with clinical and 
paraclinical signs of circulatory shock. Results of arterial gas 
analysis are shown in Table 1. A new ECG demonstrated sinus 
tachycardia, typical signs of right ventricular strain, that is, 
SIQIIITIII pattern, inverted t waves in V2, and flattened t waves 
in V3‐4 (Figure 1B). At this point, the patient was still neu-
rological intact. Ventilatory support and fluid resuscitation 
were initiated. Results of a second arterial gas analysis are 
shown in Table 1. An acute bedside echocardiogram revealed 
signs of severe right ventricular pressure overload. This in-
cluded dilatation and systolic dysfunction of the right ven-
tricle, tricuspid regurgitation and pulmonary hypertension, 
and compression and D‐sign deformation of the left ventricle 
with reduced filling despite preserved left ventricular ejec-
tion fraction (Figure 2C,D). An acute computed tomography 
pulmonary angiogram ruled out pulmonary embolism, pneu-
monia, and significant atelectasis and pleural fluid (Figure 
3A,B). Despite ongoing ventilatory support, extensive fluid 
resuscitation with >3 L isotonic saline solutions and initia-
tion of circulatory support using vasopressor agents, the pa-
tient experienced respiratory and circulatory worsening as 
well as neurological deterioration with altered mental status. 
At this point, blood samples revealed HL with a total WBC 
count of 237 × 109/L and elevated leukemic blast cell count 
of 12.6 × 109/L (Table 1). The patient’s clinical and paraclin-
ical presentation were compatible with obstructive shock and 
F I G U R E  1  Patient's 
electrocardiogram 2 mo prior to admission 
and at admission. The electrocardiogram 
was normal 2 mo prior to admission (A) but 
revealed sinus tachycardia, SIQIIITIII pattern, 
inverted t waves in V2, and flattened t waves 
in V3‐4 at admission (B)
(A)
(B)
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development of acute respiratory and right‐sided heart failure 
due to pulmonary leukostasis as a result of the transforma-
tion of MDS to AML. In addition, the patient had clinical 
and paraclinical signs compatible with leukostatic involve-
ment of the brain and kidneys. The patient was transferred to 
the intensive care unit for respiratory and circulatory support 
and initiation of induction cytoreductive chemotherapy. Due 
to the patient’s underlying malignant disease, that is, trans-
formation of MDS to AML, the patient was not considered 
candidate for extracorporeal life support. However, during 
tracheal intubation, the patient developed cardiopulmonary 
arrest and died. Because of the rapid clinical and hemody-
namic deterioration, no pathological sampling was obtained 
from the patient. An autopsy was not performed as on request 
of the patient’s relatives.
3 |  DISCUSSION
Leukostasis refers to the clinical symptoms and complica-
tions resulting from HL. However, diagnosing leukostasis 
can be challenging because of its unspecific presentation. 
Leukostasis involves several organ systems, for example, the 
central nervous system, pulmonary, cardiovascular, and pe-
ripheral vascular system. Clinical signs and symptoms may 
include fever, dyspnea, hypoxia, headache, impaired vision, 
tinnitus, confusion, somnolence, and coma.1,3 Less often, 
leukostasis presents with symptoms of myocardial and limb 
ischemia, and ECG may demonstrate signs of ischemia and 
right ventricular strain.1 In the clinical setting, the presence 
of HL, signs of altered tissue perfusion, and respiratory and 
neurological distress in patients with leukemia may guide 
the diagnosis of leukostasis.3 In the present case, leuko-
stasis was complicated by severe right‐sided heart failure. 
Consequently, in patients presenting with leukostasis and 
cardiopulmonary symptoms, clinicians should aim to assess 
for cardiac involvement, that is, by ECG and acute echocar-
diogram, since early recognition of right ventricular disease 
may provide an opportunity to treat this potentially reversible 
condition.
While pulmonary involvement is a frequent compli-
cation to leukostasis, the impact of leukostasis on right 
ventricular function using cardiovascular imaging mo-
dalities has only been sparsely reported in the literature. 
Katogiannis and colleagues reported a case of leukostasis‐
related fatal cardiopulmonary arrest as initial presentation 
of chronic myeloid leukemia with HL and a total WBC 
count of 390 × 109/L.5 Similar to the present case, echo-
cardiographic signs of severe right‐sided heart failure with 
preserved left ventricular function were also present in the 
case reported by Katogiannis and colleagues. In the present 
case, the patient experienced rapid and fatal respiratory and 
hemodynamic deterioration within a few hours because of 
leukostasis despite only moderate HL. Notably, there seems 
to be no clear correlation between WBC and leukostasis 
severity, and leukostatic symptoms may even occur with 
WBC count below 100 × 109/L.3 Other, yet unknown fac-
tors in addition to WBC count and type of leukemia may be 
important in the pathogenesis of leukostasis.1 Whether the 
timely progression of HL as well as patient comorbidities 
may contribute to leukostatic symptoms severity including 
cardiac manifestations remains speculative. Importantly, 
although the patient’s clinical and paraclinical presentation 
were compatible with pulmonary leukostasis, we cannot 
rule out microembolism of the pulmonary circulation as a 
contributing factor to the development of acute right‐sided 
heart failure in the present case due to the lack of patholog-
ical sampling.
F I G U R E  2  Patient's echocardiogram 
20 mo prior to admission and at admission. 
Echocardiographic subxiphoid 4 chamber 
(A) and short‐axis view (B) 20 mo prior to 
admission, and subxiphoid 4 chamber (C) 
and short‐axis view (D) at admission. The 
echocardiogram was normal 20 mo prior 
to admission but revealed signs of severe 
right ventricular pressure overload and 
compression and D‐sign deformation of 
the left ventricle at admission. See text for 
details
(A) (B)
(C) (D)
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Leukostasis is a medical emergency condition, and man-
agement should focus on rapid stabilization and lowering 
of the WBC count. Following stabilization of the patients, 
acute treatment of leukostasis includes cytoreduction and 
supportive care. Because chemotherapy reduces WBC 
count while at the same time targeting the leukemia itself, 
induction chemotherapy should be first choice cytoreduc-
tive strategy. The use of leukapheresis in patients with HL 
is controversial but may be used as a bridge to induction 
chemotherapy in patients with leukostasis. Supportive care 
includes (a) hydration, (b) correction of electrolyte distur-
bances, (c) prevention of tumor lysis syndrome by hydration 
and administration of allopurinol, (d) prevention of hemor-
rhage by prophylactic platelet transfusion if platelet count 
<20‐30 × 109/L, and (e) symptom‐directed supportive care, 
for example, mechanical ventilation for respiratory failure.1
This case report supports evidence of right ventricular 
failure as the cause of death in a patient with leukostasis. 
While patients with acute left‐sided heart failure typically 
present with dyspnea, hypotension, and signs of hypoper-
fusion and pulmonary edema, isolated acute right‐sided 
heart failure is characterized by dyspnea and signs of hy-
poperfusion and stasis without pulmonary edema. Cardiac 
dysfunction due to sepsis is characterized by biventricular 
dysfunction.6 In contrast, stress cardiomyopathy, also known 
as takotsubo syndrome, is predominantly characterized by 
isolated left ventricular dysfunction and only in a minority 
of patients by right ventricular involvement.7 However, it 
may be difficult to diagnose and differentiate between acute 
right‐sided and left‐sided heart failure based on clinical pre-
sentation. Moreover, ECG changes depicting right ventricu-
lar strain are not sensitive to diagnose acute right‐sided heart 
failure.8 In general, ECG findings should not stand alone9 
and diagnosis should be supported, if possible, by an acute 
echocardiogram as well as computed tomography pulmo-
nary angiogram to diagnose acute right‐sided heart failure, 
help identifying the specific underlying cause and to guide 
treatment. In addition to treatment of the specific underlying 
cause, management of acute right‐sided heart failure due to 
pulmonary hypertension includes volume unloading, right 
ventricle afterload reduction, that is, decreasing pulmonary 
vascular tone by correcting hypercapnia, acidemia and alve-
olar hypoxia, and administration of vasoactive and inotro-
pic drugs to achieve pulmonary vasodilation and improve 
right ventricle contractility. Extracorporeal life support may 
be used in acute right‐sided heart failure if medical ther-
apy is ineffective.10 Novel therapy directed toward reducing 
strain on the right ventricle, that is, percutaneous circula-
tory support and balloon atrial septostomy, might also have 
a role as a bridging strategy to induction chemotherapy in 
acute right‐sided heart failure due to leukostasis. However, 
the effect of such strategies in a setting other than familiar/
idiopathic pulmonary arterial hypertension remains contro-
versial11 and should be used with caution in order to avoid 
tumor lysis syndrome.
4 |  CONCLUSION
We document leukostasis as a complication to leukemic 
transformation of MDS leading to acute fatal right‐sided 
heart failure. Early recognition of right ventricular disease 
in patients with HL and leukostasis may provide an oppor-
tunity to treat this potentially reversible condition. Novel 
therapies directed toward reducing the strain on the fail-
ing right ventricle might have a role in the treatment of 
leukostasis.
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T A B L E  1  Results of the patient's arterial gas analyses
1. Arterial 
gas analysis
2. Arterial 
gas analysis
3. Arterial 
gas analysis
O2 supplement, 
L/min
3, nasal 15, mask w. 
reservoir
15, mask w. 
reservoir
pH (7.37‐7.45) 7.41 7.25 6.91
pCO2, kPa 
(4.3‐5.7)
3.2 3.0 4.7
pO2, kPa 
(9.6‐13.7)
11.2 8.6 13.3
Oxygen 
saturation, %
96 87 89
HCO3, mmol/L 
(21.8‐26.2)
17.5 11.9 6.8
Base excess, 
mmol/L (−5 to 
5)
−9 −16 −23
Lactate, mmol/L 
(0.5‐2.5)
3.6 9.1 12.5
Kalium, mmol/L 
(3.5‐4.6)
3.8 4.4 5.0
Natrium, mmol/L 
(136‐146)
— 137 137
Chloride, 
mmol/L 
(99‐109)
— 110 107
Creatinine, 
µmol/L (45‐90)
161 182 169
Glucose, mmol/L 
(4.2‐7.8)
8.1 10.0 8.6
Data are expressed as absolute numbers with reference intervals combined for 
men and women.
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F I G U R E  3  Patient's computed 
tomography pulmonary angiogram with 
three‐dimensional reconstruction of the 
pulmonary arteries seen from the rear. 
The computed tomography pulmonary 
angiogram revealed severe right‐sided 
dilatation (A). There was contrast filling 
in both pulmonary arteries beyond the 
segmental arteries depicted by “*”, and 
hence no signs of central pulmonary 
embolism (B). In addition, the computed 
tomography ruled out pneumonia and 
significant atelectasis and pleural fluid 
(C,D)
(A) (B)
(C) (D)
